Interleukin Restenosis Susceptibility Test Launch Expected In 2000
This article was originally published in The Gray Sheet
Executive Summary
Interleukin Genetics is seeking a diagnostics partner to market and distribute its development-stage genetic screening test for determining a patient's susceptibility to restenosis following angioplasty and stenting.
You may also be interested in...
IL-1 Gene Screening Identifies Coronary Artery Disease Susceptibility
Medical Science Systems, Inc. says it will pursue corporate partnerships to commercialize a test for the identification of a genetic risk factor for coronary artery disease.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.